Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial
Sign Up to like & getrecommendations! Published in 2024 at "Targeted Oncology"
DOI: 10.1007/s11523-024-01102-8
Abstract: Adavosertib is a first-in-class, selective small-molecule inhibitor of Wee1. Olaparib is an inhibitor of poly(ADP-ribose) polymerase (PARP). Preclinical data suggest that adavosertib enhances the antitumor effect of PARP inhibitors. The safety, tolerability, and efficacy of… read more here.
Keywords: mtd rp2d; dose expansion; part; rp2d ... See more keywords
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
Sign Up to like & getrecommendations! Published in 2022 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noac087
Abstract: Abstract Background Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1 fusion-positive non–small-cell lung cancer.… read more here.
Keywords: rp2d; ros1 alk; phase; tumors harboring ... See more keywords
Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC).
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.5017
Abstract: 5017 Background: Human kallikrein 2 (encoded by the KLK2 gene and hereafter referred to as KLK2) is a novel target expressed on PC cells with limited normal tissue expression. Pasritamig is a first-in-class T-cell-redirecting bispecific… read more here.
Keywords: pasritamig; q6w; rp2d; traes ... See more keywords